Innovative Diabetes Care with DAPASUG Range: A New Era of Glycemic Control

Apr 17, 2025

Apr 17, 2025

Managing Type 2 diabetes effectively requires access to advanced treatment options that offer both efficacy and safety. The DAPASUG range from Intra Life Pharma introduces a new era in diabetes care with its uniquely formulated oral antidiabetic medications. Let's explore four of these advanced formulations tailored for better glycemic control, cardiovascular safety, and patient compliance.

A Comprehensive Solution with DAPASUG-ST-100

Designed for adults managing Type 2 diabetes, DAPASUG-ST-100 offers a potent combination of Dapagliflozin and Sitagliptin. This novel insulin-independent antidiabetic formulation is well-known for its cardiovascular safety and effectiveness in reducing HbA1c, blood pressure, and body weight.

As a trusted manufacturer of quality diabetes medicines, Intra Life ensures that each tablet meets high standards of safety and clinical efficacy. DAPASUG-ST-100 supports metabolic control by targeting two different pathways, thereby maximizing therapeutic benefits.

DAPASUG-VD-100: Bilayered Tablet for Sustained Release

DAPASUG-VD-100 combines Dapagliflozin with Vildagliptin in a unique bilayered sustained release formulation. This therapy is especially beneficial in managing blood sugar levels throughout the day, reducing glucose fluctuations, and offering cardioprotective and renoprotective effects.

This product stands out among diabetes treatments for its dual mechanism of action and long-lasting impact. Intra Life, a reliable supplier of innovative pharmaceutical solutions, brings you DAPASUG-VD-100 to help ease the daily burden of diabetes.

DAPASUG-GM-2 Tablet: Triple-Action Oral Therapy

The DAPASUG-GM-2 Tablet is a powerful triple-drug combination of Dapagliflozin, Glimepiride, and Metformin Hydrochloride (extended release). It targets multiple metabolic pathways to achieve better glycemic control, making it a valuable option for patients with inadequately controlled Type 2 diabetes.

As a key dealer in diabetic care products, Intra Life ensures consistency, affordability, and patient adherence through this formulation. Its extended-release profile also promotes a smoother pharmacokinetic effect and better gastrointestinal tolerance.

DAPASUG-10: For Effective Monotherapy or Combination Use

DAPASUG-10 features Dapagliflozin as a single active ingredient, offering excellent monotherapy potential or compatibility with other oral antidiabetics. It helps reduce HbA1c, manage weight, and protect heart and kidney functions, all while being well-tolerated.

Trusted by doctors and patients alike, DAPASUG-10 further strengthens Intra Life’s position as a prominent exporter of dependable diabetes solutions across global markets.

Explore More Solutions

For other effective combinations like Empasug -M 500/12.5, Intra Life offers comprehensive diabetes care that addresses multiple comorbidities associated with Type 2 diabetes.